MaaT Pharma updates potential plan for MaaT013 after CHMP negative
MaaT Pharma said the EMA’s CHMP issued a negative opinion after re-examination of MaaT013 (Xervyteg®) and the company provided an update on a potential development plan.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.